Optimizing the Previs Device for Prediction of Postoperative Ileus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03505476|
Recruitment Status : Recruiting
First Posted : April 23, 2018
Last Update Posted : March 14, 2019
|Condition or disease||Intervention/treatment||Phase|
|Ileus||Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment||Not Applicable|
Following major abdominal surgery, up to 30% of patients develop a poorly understood condition known as ileus. When ileus occurs, the bowels shut down and patients often develop abdominal dissension, nausea, vomiting, and even more serious complications. Because this condition does not develop until many days after surgery has been completed, clinicians do not know if they should begin allowing patients to eat or withhold nutrition until they show signs of bowel function such as passing gas or having bowel movements. Clinicians have different approaches but none are ideal: 1) feed all patients early and the ones that develop an ileus will have their diets reverse, suction tube placed in their stomach, and hopefully don't get develop more serious complications, or 2) don't feed patients until they pass gas or have a bowel movement, which delays nutrition and prolongs hospital stays for the 70% of patients who will not develop an ileus
Participants in this study will be asked to wear a 3-ounce device that adheres to the skin of the abdominal wall for 10 days. They will also be asked to answer questions each day of their hospital stay regarding how they have tolerated eating.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||225 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||All subjects consented and enrolled will receive the same intervention. There is no control group.|
|Masking:||None (Open Label)|
|Official Title:||Optimizing the Previs Device for Prediction of Postoperative Ileus|
|Actual Study Start Date :||April 24, 2018|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||December 2021|
Experimental: Study Participants
Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
Device: Entac Medical device application
Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
Other: Patient Daily Assessment
The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
Other: Patient Discharge Assessment
The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
- Maximize the predictive value of the device for predicting postoperative GI impairment. [ Time Frame: Each patient's data will be evaluated after 14 days. Each group of 10-30 patients' data will be analyzed. Final analysis will occur after 225 patients are enrolled. ]The signal processing algorithm will be modified iteratively to maximize the negative predictive value of the device while maintaining the highest PPV The sensitivity, specificity, positive predictive value, negative predictive value, AUC, and accuracy of the device for each 10-30 patients (dependent upon the incidence of GI impairment in each group) will be measured. The signal processing algorithm will be modified iteratively to maximize the negative predictive value of the device while maintaining the highest PPV possible. Our goal is for the AUC for the final algorithm to be greater than 0.8.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03505476
|Contact: Debra OConnell Moore, MBAfirstname.lastname@example.org|
|Contact: Jessica Danielsonemail@example.com|
|United States, Iowa|
|University of Iowa||Recruiting|
|Iowa City, Iowa, United States, 52242|
|Contact: Jessica Danielson 319-356-1722 firstname.lastname@example.org|
|Contact: Kimberly Sprenger 319-353-8862 email@example.com|
|Principal Investigator:||Jennifer Hrabe||University of Iowa|